Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABL301
- Development stage
- Phase 1
- Lead developer
- ABL Bio
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ABL301 is a bispecific antibody designed to cross the blood-brain barrier (BBB) and selectively target aggregated forms of alpha-synuclein (SNCA), a protein implicated in the pathogenesis of Parkinson’s disease and multiple system atrophy. The drug combines an anti-alpha-synuclein IgG with an anti-insulin-like growth factor 1 receptor (IGF1R) single-chain variable fragment (scFv), which acts as a BBB shuttle. This design enables improved delivery of the therapeutic antibody into the brain via receptor-mediated transcytosis. Mechanistically, ABL301 facilitates microglial phagocytosis of extracellular aggregated alpha-synuclein and inhibits its cell-to-cell transmission—two processes believed to contribute to neurodegeneration in synucleinopathies. Developed by ABL Bio, it is currently in Phase 1 clinical development for Parkinson’s disease[1][2][3][5][6].
- Other names
- ABL 301ABL301ABL-301
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)aggregated α-syn (Alpha-synuclein (α-syn))
Beyond the preview
Go deeper on ABL301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABL301.